Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Dow
Johnson and Johnson
Moodys
Merck

Last Updated: December 4, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ONABOTULINUMTOXINA

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for onabotulinumtoxina

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00439140 ↗ Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder Terminated Allergan Phase 3 2007-06-01 This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
NCT00777803 ↗ NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines Completed Merz Pharmaceuticals GmbH Phase 3 2008-11-01 NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton). Injected into the muscle, NT201 causes a reversible local relaxation of the injected muscle. Botulinum toxin type A is used for aesthetic treatment of mimic wrinkles and in the therapy of neurologic diseases. This study will investigate the safety and efficacy (non-inferiority) of NT 201 in comparison with OnabotulinumtoxinA (Vistabel®) in the treatment of glabellar frown lines.
NCT00910520 ↗ Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Completed Allergan Phase 3 2009-09-01 The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
NCT00910845 ↗ Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Completed Allergan Phase 3 2009-09-01 The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
NCT01050114 ↗ OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER Unknown status Christopher Patrick Smith Phase 3 2013-08-01 Overactive bladder is a condition associated with symptoms of feeling the urge to urinate, urinating often, and may or may not be accompanied by leakage of urine. A patient who has a spinal cord injury (SCI) often suffers from an overactive bladder which often leads to urinary incontinence (UI - an unwanted leakage of urine). OnaBoNT-A bladder injections have been studied in clinical research trials. The results have shown an improvement in urinary symptoms by reducing how often urine leakage occurs and by increasing the amount of urine the bladder can hold. This purpose of this clinical trial is to see if onaBoNT-A is safe and effective when injected into the bladder for the treatment of UI and if it works better than a drug that is taken by mouth. A second purpose of the study is to perform research tests on the urine samples provided by the volunteers. Urine presents a rich source of information for bladder diseases and the biomarkers (the chemical make-up of the urine cells) will be examined to learn if there are yet undiscovered reasons for urinary diseases. These tests would be very beneficial because the results would lead to better treatment of the urinary diseases. Volunteers will be randomized to either: ARM 1: onaBoNT-A 200 U bladder injection and placebo oral capsule daily or ARM 2: Placebo bladder injection (saline) and oxybutynin ER 10mg capsule twice a day. The treatments are onaBoNT-A bladder injection and a placebo oral capsule once a day or placebo bladder injection and oxybutynin ER (like Ditropan) capsule twice a day. Placebo contains no active medicine. Participation in this study will be about 6-7 months and involve 5 visits to the clinic. The risks of bladder onaBoNT-A
NCT01071096 ↗ Calcitonin Gene-related Peptide Levels in Chronic Migraine Completed Allergan Phase 4 2010-06-01 Twenty patients will be enrolled in a 2-site, 7-month, double-blind study conducted to evaluate a reduction in headache days and attacks and calcitonin gene-related peptide (CGRP) levels in saliva following treatment with OnabotulinumtoxinA versus saline. Eligible patients will be randomized and receive injections of OnabotulinumtoxinA or Saline at Visit 1. Following 3 months plus a 1 month wash out, patients will receive cross-over injections at Visit 5. Patients will return for monthly visits and exit the study at Visit 8. Patients will collect saliva at monthly intervals and document in a daily headache diary throughout the study .
NCT01071096 ↗ Calcitonin Gene-related Peptide Levels in Chronic Migraine Completed Cady, Roger, M.D. Phase 4 2010-06-01 Twenty patients will be enrolled in a 2-site, 7-month, double-blind study conducted to evaluate a reduction in headache days and attacks and calcitonin gene-related peptide (CGRP) levels in saliva following treatment with OnabotulinumtoxinA versus saline. Eligible patients will be randomized and receive injections of OnabotulinumtoxinA or Saline at Visit 1. Following 3 months plus a 1 month wash out, patients will receive cross-over injections at Visit 5. Patients will return for monthly visits and exit the study at Visit 8. Patients will collect saliva at monthly intervals and document in a daily headache diary throughout the study .
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for onabotulinumtoxina

Condition Name

Condition Name for onabotulinumtoxina
Intervention Trials
Overactive Bladder 10
Migraine Disorders 5
Glabellar Frown Lines 5
Glabellar Lines 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for onabotulinumtoxina
Intervention Trials
Urinary Bladder, Overactive 16
Migraine Disorders 13
Urinary Incontinence 7
Muscle Spasticity 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for onabotulinumtoxina

Trials by Country

Trials by Country for onabotulinumtoxina
Location Trials
United States 253
Canada 29
United Kingdom 17
Germany 17
France 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for onabotulinumtoxina
Location Trials
California 32
Florida 18
New York 18
Texas 16
Tennessee 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for onabotulinumtoxina

Clinical Trial Phase

Clinical Trial Phase for onabotulinumtoxina
Clinical Trial Phase Trials
Phase 4 30
Phase 3 25
Phase 2/Phase 3 2
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for onabotulinumtoxina
Clinical Trial Phase Trials
Completed 53
Recruiting 17
Unknown status 9
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for onabotulinumtoxina

Sponsor Name

Sponsor Name for onabotulinumtoxina
Sponsor Trials
Allergan 46
Cady, Roger, M.D. 3
University of Wisconsin, Madison 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for onabotulinumtoxina
Sponsor Trials
Other 71
Industry 55
U.S. Fed 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Johnson and Johnson
McKesson
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.